Sinopep-Allsino Biopharmaceutical Co. Ltd. A (SHG:688076) — Market Cap & Net Worth
Market Cap & Net Worth: Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076)
Sinopep-Allsino Biopharmaceutical Co. Ltd. A (SHG:688076) has a market capitalization of $1.27 Billion (CN¥8.67 Billion) as of June 23, 2026. Listed on the SHG stock exchange, this China-based company holds position #8039 globally and #1923 in its home market, demonstrating a -1.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sinopep-Allsino Biopharmaceutical Co. Ltd. A's stock price CN¥27.43 by its total outstanding shares 316051897 (316.05 Million). Review how much debt does Sinopep-Allsino Biopharmaceutical Co. Lt carry to assess the company's total debt and financial obligations.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Market Cap History: 2021 to 2026
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows change from $1.87 Billion to $1.27 Billion (-18.17% CAGR).
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.90x
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap is 0.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.33x
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap is 5.33 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.87 Billion | $643.87 Million | $115.39 Million | 2.91x | 16.25x |
| 2022 | $1.05 Billion | $651.29 Million | $129.11 Million | 1.61x | 8.11x |
| 2023 | $2.06 Billion | $1.03 Billion | $162.94 Million | 1.99x | 12.65x |
| 2024 | $2.40 Billion | $1.62 Billion | $404.39 Million | 1.48x | 5.94x |
| 2025 | $1.74 Billion | $1.94 Billion | $327.00 Million | 0.90x | 5.33x |
Competitor Companies of 688076 by Market Capitalization
Companies near Sinopep-Allsino Biopharmaceutical Co. Ltd. A in the global market cap rankings as of June 23, 2026.
Key companies related to Sinopep-Allsino Biopharmaceutical Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap moved from $1.87 Billion to $ 1.27 Billion, with a yearly change of -18.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.27 Billion | -27.24% |
| 2025 | CN¥1.74 Billion | -27.39% |
| 2024 | CN¥2.40 Billion | +16.47% |
| 2023 | CN¥2.06 Billion | +97.02% |
| 2022 | CN¥1.05 Billion | -44.18% |
| 2021 | CN¥1.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Sinopep-Allsino Biopharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.27 Billion USD |
| MoneyControl | $1.27 Billion USD |
| MarketWatch | $1.27 Billion USD |
| marketcap.company | $1.27 Billion USD |
| Reuters | $1.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was… Read more